Frontiers in Oncology

Papers
(The H4-Index of Frontiers in Oncology is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy235
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?197
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches192
Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers177
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis163
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis146
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming144
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy139
Boron Neutron Capture Therapy: A Review of Clinical Applications138
Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma137
The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy133
Mutant p53 in Cancer Progression and Targeted Therapies133
Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship132
Artificial Convolutional Neural Network in Object Detection and Semantic Segmentation for Medical Imaging Analysis122
Obesity, Type 2 Diabetes, and Cancer Risk108
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy107
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma107
The Role of the Transcription Factor EGR1 in Cancer107
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment106
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies105
The role of IL-6/JAK2/STAT3 signaling pathway in cancers105
Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases105
Sexual Dimorphism in Colon Cancer105
A Review on Anti-Tumor Mechanisms of Coumarins105
Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications104
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects104
Has COVID-19 Affected Cancer Screening Programs? A Systematic Review103
Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib102
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion98
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism97
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer96
Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma96
Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study95
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients91
Osteosarcoma and Metastasis89
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies88
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?87
Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer87
MYCN Function in Neuroblastoma Development87
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease87
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer86
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting86
Immune Checkpoint Inhibitors in the Treatment of HCC85
Knowledge Domain and Emerging Trends in Ferroptosis Research: A Bibliometric and Knowledge-Map Analysis85
Cancer in Africa: The Untold Story85
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review85
Sintilimab: A Promising Anti-Tumor PD-1 Antibody85
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment83
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer83
Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status83
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis82
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review82
FLASH Radiotherapy: History and Future82
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents81
Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review81
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer81
EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives80
5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent80
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics80
A Review of Newly Diagnosed Glioblastoma80
The Metabolic Mechanisms of Breast Cancer Metastasis79
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters77
The Mevalonate Pathway, a Metabolic Target in Cancer Therapy76
Genome-Wide Sex and Gender Differences in Cancer76
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives75
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer75
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications75
RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy74
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank74
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma73
The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development72
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy72
0.058530807495117